YUPELRI

REVEFENACIN

Manufacturer: Mylan Specialty L.P.

Score: 141.0

Quick Summary

YUPELRI is a long-acting muscarinic antagonist used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It works by inhibiting the M3 receptor in the airways, leading to bronchodilation. The recommended dosage is 175 mcg once daily by oral inhalation via a standard jet nebulizer. YUPELRI has been shown to be effective in improving lung function and reducing symptoms in patients with COPD. However, it is contraindicated in patients with hypersensitivity to revefenacin or any component of the product, and caution should be exercised in patients with narrow-angle glaucoma, urinary retention, or other conditions that may be exacerbated by anticholinergic therapy.

Key Clinical Findings and Indications

Maintenance treatment of COPD
Long-acting muscarinic antagonist
Improves lung function and reduces symptoms in patients with COPD

Important Safety Information

Warning

Contraindicated in patients with hypersensitivity to revefenacin or any component of the product

Contraindications

Hypersensitivity to revefenacin or any component of the product

Adverse Reactions

Paradoxical bronchospasm
Worsening of narrow-angle glaucoma
Worsening of urinary retention
Immediate hypersensitivity reactions
Cough
Nasopharyngitis
Upper respiratory tract infection
Headache
Back pain

Dosing Recommendations

General Guidance

No dosage adjustment is required for geriatric patients or patients with renal impairment

COPD

Adult Dose

175 mcg once daily by oral inhalation via a standard jet nebulizer

Pediatric Dose

Not indicated for use in children

Special Population Considerations

Pregnancy

There are no adequate and well-controlled studies with YUPELRI in pregnant women
Women should be advised to contact their physician if they become pregnant while taking YUPELRI

Nursing Mothers

Pediatric Use

The safety and effectiveness of YUPELRI have not been established in pediatric patients
YUPELRI is not indicated for use in children

Geriatric Use

No overall differences in safety or effectiveness were observed between geriatric patients and younger patients
Greater sensitivity of some older individuals cannot be ruled out

Similar Drugs

Spiriva Respimat

TIOTROPIUM BROMIDE INHALATION SPRAY

Boehringer Ingelheim Pharmaceuticals, Inc.

Similarity: 63.3%